Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A pancreatic cancer cells spectral library and the phenotype analysis of gemcitabine-sensitive and -resistant pancreatic cell lines by the data-independent acquisition proteome strategy

ABSTRACT: Based on data-independent acquisition (DIA)-mass spectrometry (MS) strategies for in-depth proteome analysis, we established a high-coverage spectrum library from seven human pancreatic cell lines and evaluated performance of the library by exploring the molecular change between gemcitabine (GEM) sensitivity and resistance phenotypes .

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Cell Culture

DISEASE(S): Disease Free

SUBMITTER: Ran Kong

LAB HEAD: State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China corresponding author: Wantao Ying (e-mail: yingwantao@ncpsb.org.cn.)

PROVIDER: PXD030948 | Pride | 2022-05-31

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Similar Datasets

Establishment of pancreatic cancer cells spectral library based on data-independent acquisition strategy and the phenotype analysis of pancreatic cell lines of the sensitivity and resistance of gemcitabine

Project description:Based on data-independent acquisition (DIA)-mass spectrometry (MS) proteomics, we first established a high-coverage human pancreatic cells spectrum library. Furthermore, analyzed the sensitivity and drug resistance phenotypes to gemcitabine (GEM).

2022-05-31 | PXD031028 | Pride

Characterisation of pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling

Project description:Here we use high-resolution mass spectrometry (MS) to characterise the magnitude and complexity of global tyrosine phosphorylation PDAC. We profiled the endogenous tyrosine phosphorylation-based signaling in 36 cell lines from two cell line populations, quantifying around 2,000 tyrosine phosphorylation sites. This approach facilitated consistent segregation of PDAC cell lines into three subtypes with distinct signalling profiles, using both their global tyrosine phosphorylation patterns and a Random Forest derived 8 phosphorylation site signature. We extracted segregation-driving phosphosites, and subsequent pathway and network analysis to characterise the identified subtypes.

2016-06-09 | PXD003198 | Pride

Rintatolimod induces antiviral activities in human pancreatic cancer cells: opening for an anti-COVID-19 opportunity in cancer patients?

Project description:Severe acute respiratory virus-2 (SARS-CoV2) has spread globally leading to a devastating loss of life. Large registry studies have begun to shed light on the epidemiological and clinical vulnerabilities of cancer patients who succumb to or endure poor outcomes of SARS-CoV-2. Specific treatment for COVID-19 infections in cancer patients is lacking while the demand for treatment is increasing. Therefore, we explored the effect of Rintatolimod (Ampligen), a Toll-like receptor 3 (TLR3) agonist, to treat uninfected human pancreatic cancer cells (HPACs). The direct effect of Rintatolimod was measured by targeted gene expression profiling and by proteomics measurements. Our results showed that Rintatolimod induces an antiviral effect in HPACs by inducing RNase L- dependent and independent pathways of the innate immune system. Treatment with Rintatolimod activated the interferon signaling pathway, leading to the overexpression of several cytokines and chemokines in epithelial cells. Furthermore, Rintatolimod treatment increased the expression of angiogenesis-related genes without promoting fibrosis, which is the main cause of death in COVID-19 infected patients. We conclude that Rintatolimod could be considered an early additional treatment option for cancer patients who are infected with SARS-CoV-2 to prevent the complicated severity of the disease.

2022-02-17 | PXD026116 | Pride

Pancreatic cell lines MS2/MS3 TMT labeled Rescored with Prosit

Project description:We Have a pancreas MS2/MS3 dataset in this project. We predict all spectra in the datasets via Prosit then rescore. We have 100% FDR maxquant search results, and using percolator we get 1%FDR filtered results with andromeda Scores and another with features extracted from Prosit predictions.

2022-06-09 | PXD030342 | Pride

Affymetrix array of three pancreatic cancer cells treated with tumour treating fields upon combination with mild hyperthermia

Project description:Tumor Treating Fields (TTFields) disturbs mitosis and consequently leads to cell cycle arrest and cell death. Mild hyperthermia induces cancer cell death by apoptosis,leading to DNA damage and disturbing DNA repair. Thus, when mild hyperthermia is combined with TTFields, the anti-tumor effect could be augmented. This prompted the hypothesis for the present thesis: TTFields and mild hyperthermia as synergistic modalities in Pancreatic ductal adenocarcinoma (PDAC) treatment could probably enhance antitumor efficacy and abate individual toxic effects through distinct and overlapping mechanisms target the tumor cell. Our established PDAC cell line (Bx-GEM) was treated with TTFields and TTFields with mild hyperthermia and was examined by microarray. 500 ng mRNA was checked for quality control and the concentration was measured again. Subsequently, gene expression profiling was performed using human HuGene-2_0-st-type array from Affymetrix.

2021-03-17 | E-MTAB-10270 | biostudies-arrayexpress

Gene expression profiling of gemcitabine sensitive BxPC-3 pancreatic cancer cell lines and their derived resistant subclones, Bx-GEM

Project description:This experiment describes the differential gene expression between parental gemcitabine-sensitive BxPC-3 cells and their resistant subclones, Bx-GEM. To select for the resistant subclones, parental BxPC-3 cells were treated with increasing concentrations of gemcitabine (10, 25, 50, 100 and 200 nM) for more than one year. Cells resistant at each stage of drug dosing were re-cultured in the subsequent dose, and their resistance confirmed via cell viability assays. Subclones resistant to 200 nM gemcitabine, in additon to the parental cells were used for gene profiling by array. Total RNA was extracted from the cells using the miRNeasy Mini Kit (Qiagen). The Illumina TotalPrep RNA Amplification Kit (life technologie) was used to generate single-stranded cRNA from input amounts of 500ng total RNA. 1,5 ug of cRNA were hybridized for 17 hr at 58Â°C on Illumina human HT12-Microarray using the Standard Illumina Hybridisation Protocol Part # 11322355 (Whole-Genome Gene Expression Direct Hybridization Assay Guide). Gene Expression Microarrays were scanned using the Illumina iScan-Scanner according to the Standard Illumina Scanning Protocol Part # 11322355 (Whole-Genome Gene Expression Direct Hybridization Assay Guide).

2017-01-20 | E-MTAB-4901 | biostudies-arrayexpress

Gene expression profiling of pancreatic cancer cell line BxPC-3 induced by PAR-2 AP

Project description:Protease-activated receptor-2 (PAR-2), a G protein-coupled receptor activated by trypsin and coagulant factors, plays broad spectrum of physiological and pathological roles especially in cancer development. In this study, we used PAR-2 activating peptide to mimic the action of trypsin to trigger PAR-2 signaling pathway and effects of PAR-2 activation on gene expression in human pancreatic cancer cell line BxPC-3 investigated by microarray analysis. Through DAVID bioinformatic resources, we observed that activated PAR-2-mediated genes are summarized to two different pathways, renal cell carcinoma and NFkB pathway. In renal cell carcinoma pathway, activated PAR-2 dysregulated hypoxia-inducible factors and its target genes, including glucose transporter 1 (GLUT1), transforming growth factor-b (TGF-b) and vascular endothelial growth factor-A (VEGF-A). In addition, activated PAR-2 induced MAPK signaling and transcriptional factors, such as JUN, MAP2K1 and ETS1. The regulation of these genes by PAR-2 assumed that PAR-2 signaling was associated with cancer progression. On the other hand, activated PAR-2 upregulated interleukin-1b (IL-1b) and toll-like receptor 4 (TLR4) related with NFkB activation, which indicated that PAR-2 signaling may cause cancer-related inflammation. In conclusion, PAR-2 may be a factor to regulate cancer progression and inflammation. Two-condition experiment, control cells vs PAR-2 AP-treated cells.

2013-04-30 | E-GEOD-44827 | biostudies-arrayexpress

Multi-omics Study Reveals the Synergistic Anti-tumor Effects of Aspirin and Gemcitabine-based Chemotherapy on Pancreatic Cancer and the Underlying Mechanism

2023-09-08 | E-MTAB-11517 | biostudies-arrayexpress

Multi-omics Study Reveals the Synergistic Anti-tumor Effects of Aspirin and Gemcitabine-based Chemotherapy on Pancreatic Cancer and the Underlying Mechanism

Project description:Pancreatic cancer is a highly malignant tumor that is well known for its poor prognosis. It has been reported that aspirin can reduce the risk of various cancers, but the potential role of aspirin and gemcitabine in pancreatic cancer pathogenesis and chemotherapy has not been studied. Therefore, we investigated their synergistic anti-tumor effects and explored the potential molecular mechanisms and biological functions underlying their inhibitory effects on the development of pancreatic cancer in the hope of identifying treatment-related or prognostic biomarkers for the effective treatment of pancreatic cancer.

2022-05-31 | PXD031910 | Pride

Pancreatic cells spectral library by the DIA strategy and the phenotype analysis of gemcitabine-sensitive

Project description:Data-independent acquisition (DIA)-mass spectrometry (MS) based proteome strategies is increasingly used for detecting and validating protein biomarkers and therapeutic targets. Here, by in-depth proteome analysis of 7 pancreatic cell lines, we built a pancreas-specific mass spectrum library containing 10633 protein groups and 184551 peptides.

2022-05-31 | PXD032263 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data